S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
F   9.08 (+0.44%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
F   9.08 (+0.44%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

Theragenics Stock Price, Forecast & Analysis (NYSE:TGX)

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 02/14/2019)
Today's Range
Now: $0.12
50-Day Range N/A
52-Week Range N/A
Volume2,160 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Theragenics Corporation is a medical device company serving the surgical products and cancer treatment markets. The Company operates in two business segments: surgical products segment and brachytherapy seed segment. The Company's surgical products business manufactures, markets and sells disposable devices primarily utilized in certain surgical procedures. The Company's brachytherapy seed business manufactures, markets and sells radioactive seeds primarily utilized in the treatment of early stage prostate cancer. The Company designs , manufactures, assembles, packages and distributes its surgical products in three primary production facilities, each of which manufactures different products. In October 2013, the Company announced that it has completed the merger with Juniper Acquisition Corporation.

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive TGX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGX and its competitors with MarketBeat's FREE daily newsletter.

Theragenics (NYSE:TGX) Frequently Asked Questions

What is Theragenics' stock symbol?

Theragenics trades on the New York Stock Exchange (NYSE) under the ticker symbol "TGX."

Has Theragenics been receiving favorable news coverage?

Media stories about TGX stock have trended very negative on Monday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Theragenics earned a news impact score of -3.2 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Theragenics.

What other stocks do shareholders of Theragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theragenics investors own include Aphria (APHA), Bombardier, Inc. Class B (BBD.B), Eldorado Gold (EGO), Canopy Growth (CGC) and Hologic (HOLX).

What is Theragenics' stock price today?

One share of TGX stock can currently be purchased for approximately $0.12.

What is Theragenics' official website?

The official website for Theragenics is http://www.theragenics.com/.

How can I contact Theragenics?

Theragenics' mailing address is 5203 Bristol Industrial Way, BUFORD, GA 30518, United States. The medical device company can be reached via phone at +1-770-8315137.

MarketBeat Community Rating for Theragenics (NYSE TGX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about Theragenics and other stocks. Vote "Outperform" if you believe TGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Featured Article: Blue-Chip Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel